Epidemiology of thyroid disorders in the Lifelines Cohort Study (the Netherlands)

Hanneke J. C. M. Wouters¹, Sandra N. Slagter¹, Anneke C. Muller Kobold², Melanie M. van der Klauw¹, Bruce H. R. Wolffenbuttel¹*

¹ Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, ² Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

* bwo@umcg.nl

Abstract

Background
Thyroid hormone plays a pivotal role in human metabolism. In epidemiologic studies, adequate registration of thyroid disorders is warranted. We examined the prevalence of thyroid disorders, reported thyroid medication use, thyroid hormone levels, and validity of thyroid data obtained from questionnaires in the Lifelines Cohort Study.

Methods
We evaluated baseline data of all 152180 subjects (aged 18–93 years) of the Lifelines Cohort Study. At baseline, participants were asked about previous thyroid surgery and current and previous thyroid hormone use. At follow-up (n = 136776, after median 43 months), incident thyroid disorders could be reported in an open, non-structured question. Data on baseline thyroid hormone measurements (TSH, FT4 and FT3) were available in a subset of 39935 participants.

Results
Of the 152180 participants, mean (±SD) age was 44.6±13.1 years and 58.5% were female. Thyroid medication was used by 4790 participants (3.1%); the majority (98.2%) used levothyroxine, and 88% were females. 59.3% of levothyroxine users had normal TSH levels. The prevalence of abnormal TSH levels in those not using thyroid medication was 10.8%; 9.4% had a mildly elevated (4.01–10.0 mIU/L), 0.7% had suppressed (<0.40 mIU/L), while 0.7% had elevated (>10.0 mIU/L) TSH levels. Over 98% of subjects with TSH between 4 and 10 mIU/L had normal FT4. Open text questions allowing to report previous thyroid surgery and incident thyroid disorders proved not to be reliable and severely underestimated the true incidence and prevalence of thyroid disorders.

Conclusions
Undetected thyroid disorders were prevalent in the general population, whereas the prevalence of thyroid medication use was 3.1%. Less than 60% of individuals using levothyroxine...
had a normal TSH level. The large group of individuals with subclinical hypothyroidism (9.4%) offers an excellent possibility to prospectively follow the natural course of this disorder. Both structured questions as well as linking to G.P.’s and pharmacists’ data are necessary to improve the completeness and reliability of Lifelines’ data on thyroid disorders.

Introduction

Thyroid hormone plays a pivotal role in human metabolism. It is important in all processes in the body, including metabolic pathways, growth, development, cognition, energy homeostasis and temperature regulation. Peripheral thyroid hormone levels are closely regulated by the pituitary gland. Disorders of thyroid function are frequently diagnosed, with prevalences varying between 2 and 6% in large population-based studies [1–3].

Thyroid disorders and their treatment may have a great impact on long-term health. Thyrotoxicosis and even mild (subclinical) hyperthyroidism are associated with a higher risk of cardiovascular problems and osteoporosis [4–7], while hypothyroidism has been associated with dyslipidaemia, atherosclerosis and also an increased risk of cardiovascular events [8–11]. Over-substitution of levothyroxine in individuals with a thyroid disorder accounted for approximately half of both prevalent and incident suppressed thyroid stimulating hormone (TSH) findings in a community-based cohort, especially among older women, which increases their risk of atrial fibrillation and osteoporosis [12]. In order to assess the (life-time) consequences of mild thyroid dysfunction and thyroid disorders in epidemiologic studies, adequate registration of such disorders, the use of medication influencing thyroid function, and degree of control of thyroid dysfunction is necessary. Hypothyroidism may not be readily recognized, or remain even asymptomatic for a -yet unknown- period [3, 13], leading to a longer exposure to low thyroid hormone levels. More severe suppression of TSH in individuals treated for hypothyroidism and thyroid cancer has been associated with a higher incidence of cardiovascular events and osteoporosis [14, 15].

Biobanks offer the unique possibility to retrieve earlier serum samples to evaluate preceding thyroid hormone levels, especially when repeated evaluation and sample collection in their participants is performed. The Lifelines Cohort Study is such a biobank, examining in a unique three-generation design the health and health-related behaviours of the habitants in the North of the Netherlands. In this study, we examine the prevalence of thyroid disorders, thyroid hormone use, and thyroid hormone levels in the Lifelines Cohort Study. Results are compared with similar data obtained in other population-based studies and in the Dutch G.P. morbidity registry for validation purposes.

Materials and methods

Participants

Subjects included were participants in the Lifelines Cohort Study, a multi-disciplinary prospective population-based cohort study examining in a unique three-generation design the health and health-related behaviours of 167729 persons living in the North of The Netherlands. It employs a broad range of investigative procedures in assessing the biomedical, socio-demographic, behavioural, physical and psychological factors which contribute to the health and disease of the general population, with a special focus on multi-morbidity and complex genetics [16–18]. It was demonstrated that the Lifelines adult study population is broadly representative
for the adult population of the North of the Netherlands [19]. All participants have provided written informed consent before participating in the study, which has been approved by the Medical Ethics Review Committee of the University Medical Center Groningen.

For the present study, we evaluated the data of all 152180 subjects between 18 and 93 years of age who underwent a baseline examination between January 2007 and December 2013. In addition, follow-up data which have been collected between January 2014 and January 2017 were available for analysis in 136776 participants. Of these, 98626 had filled in follow-up questionnaires and underwent follow-up measurements, while in 38150 only interim questionnaire data were available. Median follow-up until the last questionnaire was 43 months (range 11 to 133 months).

Measurement of thyroid hormone levels, i.e. TSH, free thyroxine (FT4) and free triiodothyronine (FT3), started in November 2009. As Lifelines decided to stop the measurement of thyroid hormones in November 2011, these measurements were only available and complete in a subset of 39935 participants. There was no clinically relevant difference in sex distribution, age and body mass index (BMI) between those with and without thyroid hormone levels measured. In 37741 of these 39935 participants, follow-up data were available. Of these, 30050 had filled in follow-up questionnaires and underwent follow-up measurements, while in 7691 only interim questionnaire data were available. Median follow-up in this subgroup was 48 months (range 12 to 112 months).

### Questionnaires and clinical examination

The specific methodology employed by Lifelines has been described previously [17, 20, 21]. At both baseline and follow-up examination, participants completed a self-administered questionnaire on medical history and past and current diseases. The catalogue of these questionnaires can be browsed at [https://www.lifelines.nl](https://www.lifelines.nl). A limited number of participants (3%) was not able to fill in the questionnaires themselves; for those participants a proxy questionnaire was used and filled in by a close relative. The proxy questionnaire was considerably shorter than the full questionnaires. Questions related to thyroid disorders have been summarised in Table 1. During the baseline examination, participants were asked about current and previous use of medication for a thyroid disorder (HEALTH66/67), and concomitant thyroid disorders (HEALTH73). Previous thyroid surgery (HEALTH74) could be reported by participants in an open, non-structured question. During follow-up, no structured questions regarding thyroid disorders or medication use were asked, therefore *incident* thyroid disorders were based on self-report obtained from an open, non-structured question (HEALTH100).

**Table 1. Content of the questionnaires.**

| Question# | Description in the questionnaire                                                                 |
|-----------|---------------------------------------------------------------------------------------------------|
| Baseline  |                                                                                                  |
| HEALTH66  | Do you currently use medication for an overactive or underactive thyroid?                           | Yes / No                                           |
| HEALTH67  | Have you used medication for an overactive or underactive thyroid in the past?                    | Yes / No                                           |
| HEALTH73  | Do you have or have you had another disorder that you have not mentioned yet?                     | Yes / No                                           |
|           | If you have had another disorder, what disorder?                                                   | Open text answer                                   |
| HEALTH74  | If you ever had surgery, what was the reason for the surgery?                                     | Open text answer                                   |
| Follow-up |                                                                                                  |
| HEALTH100 | Could you indicate which other health problems you have (had) since the last time you filled out this questionnaire? | Open text answer                                   |

# once every 1.5 years.

[https://doi.org/10.1371/journal.pone.0242795.t001](https://doi.org/10.1371/journal.pone.0242795.t001)
Medication use was verified at baseline by a certified research assistant, and scored by the Anatomical Therapeutic Chemical (ATC) Classification System, a system developed for the classification of active ingredients of drugs. We discriminated between the use of levothyroxine (ATC code H03AA01), liothyronine (ATC H03AA02), and thyroid blockers (methimazole or propylthiouracil, ATC code H03BA and H03BB). For most evaluations, we excluded 60 participants using amiodarone (ATC code C01BD01), as this drug may significantly alter thyroid hormone levels [22]. Structured ascertainment of thyroid disorders or medication use by Lifelines participants with the use of other sources, like general practitioners’ or pharmacists’ data, was not performed.

A standardised protocol was used to obtain blood pressure and anthropometric measurements: height, weight, and waist circumference. Weight was measured to the nearest 0.1 kg and height and waist circumference to the nearest 0.5 cm by the research assistant using calibrated measuring equipment, with participants wearing light clothing and no shoes. Waist circumference was measured with a tape around the body between the lower rib margin and the iliac crest. BMI was calculated as weight divided by height squared (kg/m$^2$). Systolic and diastolic blood pressure (BP) and heart rate were measured every minute for 10 minutes in the supine position using an automated Dinamap Monitor (GE Healthcare, Freiburg, Germany). The average of the last three readings was recorded for each blood pressure parameter and heart rate.

**Prevalence and incidence comparison with other sources**

For comparison with Lifelines epidemiologic data, we have assessed the prevalence of hypothyroidism (International Classification of Primary Care (ICPC) T86) as collected by NIVEL (Netherlands Institute for Health Services Research) through registration by G.P.’s. This public dataset was created in March 2014, and comprised data on incidence and prevalence of hypothyroidism during the year 2013.

Our second source for comparison was NHANES, a cross-sectional survey in the USA that uses a complex, stratified, multistage sampling design [23, 24]. We used data from NHANES 2007–2008, 2009–2010 and 2011–2012 participants who were aged 18 years and above, and had serum TSH measurements available (n = 9209). Written informed consent was obtained from all participants; the survey protocol was approved by the Research Ethics Review Board of the National Center for Health Statistics. Interviews, examination response rates, methodology and results are publicly available [25]. Hypothyroidism was defined as the use of levothyroxine.

**Biochemical measurements**

Blood samples were taken in the fasting state between 8:00 and 10:00 a.m. and transported to the laboratory facility at room temperature or 4°C, depending on the sample requirements. All measurements were performed the same day. Levels of TSH, FT4 and FT3 were assayed by electrochemiluminescence immunoassay (Roche Modular E170, Roche, Switzerland). Glycated haemoglobin (HbA1c, EDTA-anticoagulated) was analysed using an NGSP-certified turbidimetric inhibition immunoassay on a Cobas Integra 800 CTS analyser (Roche Diagnostics BV, Almere, The Netherlands). Serum creatinine was measured on a Roche Modular P chemistry analyser (Roche, Basel, Switzerland). Total and high density lipoprotein (HDL) cholesterol were measured using an enzymatic colorimetric method, triglycerides using a colorimetric UV method, and low density lipoprotein (LDL) cholesterol using an enzymatic method, on a Roche Modular P chemistry analyser (Roche, Basel, Switzerland). Fasting blood glucose was measured using a hexokinase method. The general Dutch population is iodine sufficient [26]. Anti-thyroid peroxidase antibody levels were not available.
Definitions of concomitant morbidities, calculations, and statistical analyses

Diagnosis of metabolic syndrome was established if a subject satisfied at least three out of five criteria according to the modified guidelines of the National Cholesterol Education Programs Adults Treatment Panel III (NCEP ATPIII criteria): 1. systolic blood pressure \( \geq 130 \) mmHg and/or diastolic blood pressure \( \geq 85 \) mmHg and/or use of antihypertensive medication; 2. HDL cholesterol levels \(< 1.03 \) mmol/L in men and \(< 1.30 \) mmol/L in women and/or use of lipid-lowering medication influencing HDL levels; 3. triglyceride levels \( \geq 1.70 \) mmol/L and/or use of triglyceride-lowering medication; 4. waist circumference \( \geq 102 \) cm in men and \( \geq 88 \) cm in women; 5. fasting glucose level \( \geq 5.6 \) mmol/L and/or use of blood glucose-lowering medication and/or diagnosis of type 2 diabetes [27]. Diagnosis of type 2 diabetes was by self-report, use of oral blood-glucose-lowering agents or insulin, or a fasting blood glucose \( \geq 7.0 \) mmol/L, and/or a HbA1c \( \geq 6.5\% \) at baseline laboratory evaluation. Use of statins and blood-pressure-lowering drugs was assessed based on the ATC codes of verified medication use (statins: ATC code C10AA••; BP-lowering drugs: ATC codes C02••, C03••, C04••, C07••, C08••, C09••).

We cross-tabulated verified medication use with the answers to questions HEALTH66 and HEALTH67 (self-reported current and previous use of medication for a thyroid disorder, Table 2). The percentage of users of thyroid hormone medication were calculated per age group for the entire cohort. In those participants with available thyroid hormone measurements, mean levels of TSH, FT4 and FT3 were calculated according to the use of levothyroxine. For these calculations, participants using liothyronine and thyroid hormone blockers were excluded. Participants were divided into subgroups according to serum TSH values (1st: suppressed, TSH \(< 0.40 \) mIU/L; 2nd: euthyroid, TSH 0.40–4.0 mIU/L (reference group); 3rd: mildly elevated, TSH 4.01–10.0 mIU/L, also defined as subclinical hypothyroidism; 4th: markedly elevated, TSH \( > 10.0 \) mIU/L, overt hypothyroidism). The percentage of users of thyroid hormone and distribution of TSH class was calculated for all age-decade groups (18–29, 30–39, 40–49, 50–59, 60–69, 70–79, \( \geq 80 \) years). For comparison of Lifelines with NIVEL and NHANES data, the prevalence of thyroid hormone use was calculated for the age groups 18–44, 45–64, 65–74, 75–84, and \( \geq 85 \) years, since these were the age groups used by NIVEL. Local laboratory reference values for FT4 were 11–20 pmol/L, for FT3 4.4–6.7 pmol/L.

All answers to the open questions HEALTH73, HEALTH74 and HEALTH100 which were related to thyroid disorders were scored according to the most likely diagnosis or reason for surgery: 1. Hypothyroidism; 2. Hyperthyroidism not specified; 3. Graves’ disease; 4. Nodular disease or goiter; 5. Thyroid cancer; 6. Thyroiditis; 7. Thyroid disorder not specified.

### Table 2. Current use of medication for a thyroid disorder (question HEALTH66).

| Are you currently using medication for a thyroid disorder? | Yes | No | Missing | Total |
|----------------------------------------------------------|-----|----|---------|-------|
| Cross-check with medication overview list                |     |    |         |       |
| Levothyroxine                                            | 4416 (96.4%) | 56 (<0.1%) | 231 (6.3%) | 4703 |
| Liothyronine                                             | 68 (1.5%) | <10 (<0.1%) | 0 (0%) | n.a. |
| Thyroid blocker                                          | 106 (2.3%) | <10 (<0.1%) | <10 (<0.1%) | n.a. |
| Animal source of thyroid hormone                         | 19 (0.4%) | <10 (<0.1%) | <10 (<0.1%) | n.a. |
| Any of the above*                                         | 4491 (98.1%) | 63 (0.04%) | 236 (6.3%) | 4790 |
| No medication used / reported                            | 88 (1.9%) | 143807 (>99%) | 3495 (93.7%) | 147390 |

* a participant could use one or more of these medications.

https://doi.org/10.1371/journal.pone.0242795.t002
All analyses were conducted using SPSS Statistics (Version 22, IBM, Armonk, NY, USA). Data are presented as mean ± SD, or median and IQR (interquartile range) when not normally distributed, or percentages. Means were compared between groups with analysis of variance. When variables were not normally distributed, medians were compared with the nonparametric Mann-Whitney U test. Chi-square test was used to analyse categorical variables. P-values < 0.05 were considered statistically significant.

Results

Baseline dataset

S1 Table shows the most relevant baseline parameters for the participants according to levothyroxine use. Of the 152180 participants, 89050 (58.5%) were female. Mean age was 44.6 (SD 13.1, range 18–93) years, and mean BMI was 26.1 (SD 4.3, range 13.4–73.6) kg/m². Participants reporting the use of thyroid hormone were older, had a higher BMI, and were more frequently female and obese (BMI >30 kg/m²). They were also less healthy as they had higher glucose, HbA1c and total cholesterol and triglyceride levels, more frequently had metabolic syndrome or type 2 diabetes, and used a higher number of medications including statins and antihypertensive medication.

Thyroid disease based on current and previous medication use

The question on current use of medication for an underactive or overactive thyroid was answered positively by 4579 participants (3.0% of total). The majority of them (96.4%) reported the use of levothyroxine (Table 2). Of those reporting no use of medication, 63 (0.04%) did use thyroid medication according to the verifications of the medication list, again the majority using levothyroxine. An answer to this question was missing in 3731 participants, as this question was not part of the proxy questionnaire. Still, 236 (6.3%) of them were using medication according to the verified medication list, bringing the total users of medication to 4790 (= 3.1% of the total population). In total 118 participants (0.08%) used a thyroid blocker indicating active treatment for thyrotoxicosis.

A total of 3169 participants reported at baseline that they have used medication for an underactive or overactive thyroid in the past. Of these, 1800 (56.8%) were still using any type of thyroid medication at the baseline visit according to the verified medication list. This indicates the low discriminatory power of this question to indicate earlier but not current use of any thyroid medication. Fig 1 shows the distribution of levothyroxine use per age group. There is a clear increase with age, and for all age groups a 1:5 to 1:6 male:female ratio. The overall prevalence of levothyroxine use was 3.1% (0.9% in men and 4.7% in women).

In Table 3, we compared the incidence and prevalence of hypothyroidism (ICPC code T86) of the NIVEL G.P. registration with the prevalence of hypothyroidism (defined as levothyroxine use) in Lifelines. The prevalence of hypothyroidism in male participants was similar, but in females the prevalence of hypothyroidism appeared to be higher in Lifelines for almost all age groups, except those ≥85 years. In addition, we compared our data to NHANES. In NHANES the prevalence of hypothyroidism (defined as any use of thyroid hormone) was higher than that in Lifelines, especially for individuals >45 years in both males and females.

Thyroid hormone levels

In 39935 participants, thyroid hormone levels were available. For the subsequent analyses, we excluded users of methimazole, propylthiouracil, animal source of thyroid hormone and/or
Table 3. Incidence and prevalence of hypothyroidism (in number per 1000).

| Age group | Total | Incidence NIVEL<sup>a</sup> | Prevalence NIVEL<sup>a</sup> | Prevalence NHANES<sup>b</sup> | Prevalence Lifelines<sup>c</sup> |
|-----------|-------|-----------------------------|-----------------------------|-------------------------------|----------------------------------|
|           |       | 4.3                         | 21.8                        | unknown                       | unknown                          |
| 0–4 yrs   |       | 0.3                         | 0.1                         | NA                            | NA                               |
| 5–17 yrs  |       | 0.3                         | 0.8                         | NA                            | NA                               |
| 18–44 yrs |       | 0.9                         | 5.1                         | 3.5                           | 22.1                            |
| 45–64 yrs |       | 2.3                         | 9.3                         | 10.3                          | 22.1                            |
| 65–74 yrs |       | 4.2                         | 123                         | 18.4                          | 74                              |
| 75–84 yrs |       | 5.4                         | 14.9                        | 26.4                          | 77.5                            |
| ≥85 yrs   |       | 8.5                         | 14.8                        | 30.5                          | 73.4                            |

Sources:

<sup>a</sup> Open access NIVEL Registration of Care by G.P.’s, accessed March 2014, based on diagnosis code T86, registered by a G.P.

<sup>b,c</sup> Based on use of thyroid hormone supplementation.

https://doi.org/10.1371/journal.pone.0242795.t003
Participants using levothyroxine had higher FT4 and lower FT3 compared to those not using levothyroxine, with comparable TSH concentrations (S2 Table).

As shown in Table 4, prevalence of abnormal thyroid hormone levels in those not using thyroid medication was 10.8%; 9.4% had a mildly elevated TSH level (4.01–10.0 mIU/L, subclinical hypothyroidism), 0.7% had a suppressed TSH level (<0.4 mIU/L), while 0.7% had elevated TSH (>10 mIU/L, overt hypothyroidism). Fig 2 shows the inverse relationship between TSH and FT4 levels in individuals with elevated TSH (>4.0 mIU/L) not using levothyroxine. In total, 3600 of 3660 participants (98.4%) with TSH between 4.01 and 10.0 mIU/L still had a normal FT4 (>11.0 pmol/L). Of those with TSH >10.0 mIU/L, 61% had FT4 levels within the reference range. In participants using levothyroxine, less than 60% had TSH levels within the reference range of 0.40–4.0 mIU/L, 13.7% had suppressed TSH, while 27.0% had elevated TSH levels (Table 4). Prevalence of suppressed TSH gradually increased with increasing age in non-users (Table 5). With the exception of the high prevalence of subclinical hypothyroidism in those aged 18–29 years (13%), there is also a gradual increase of prevalence of subclinical hypothyroidism with ageing. For comparison, S3 Table shows similar data for NHANES. Compared to Lifelines, NHANES observed an overall higher prevalence of suppressed TSH, whereas the percentage of individuals with mildly or severely elevated TSH was lower.

Validation of self-reported thyroid disorders and / or surgery

A total of 282 participants answered in question HEALTH73 that they had a thyroid disorder (S4 Table). Only 49 of them had answered ‘yes’ to either question HEALTH66 or HEALTH67 related to medication use for an overactive or underactive thyroid. The majority reported hypothyroidism. Considering the large difference between this question HEALTH73 and questions HEALTH66/67, these data must be considered as incomplete. A total number of 674 participants (0.4%) reported in the open question on surgery (HEALTH74) that they previously had undergone thyroid surgery (S4 Table). Over 50% reported no specific reason for their surgery.

S5 Table shows the number of participants reporting a new thyroid disorder in one of the follow-up questionnaires (question HEALTH100). Hypothyroidism and an unspecified thyroid disorder (the participant did not specify the nature of the thyroid disorder) were reported most frequently. Based on the number of participants and the duration of follow-up, this would suggest an incidence of hypothyroidism between 1.6 and 2.3 per 1000 individuals per year, and a total incidence of thyroid disorders of 3.1 per 1000 individuals per year. These incidence data are considerably lower than the incidence of hypothyroidism as collected by Dutch G.P.’s (Table 3). Unfortunately, the development of new thyroid disorders reported by Lifelines participants could not be checked with G.P. datasets or new medication use. However, in the subgroup of participants with available TSH levels at baseline, we were able to ascertain

| Table 4. Distribution of TSH class in participants according to levothyroxine use. |
|---------------------------------------------------------------|
| **No levothyroxine** | **Levothyroxine** |
|----------------------|-------------------|
| **M** | **F** | **M** | **F** |
| **TSH <0.4 mIU/L** | 265 (0.7%) | 91 | 174 | 155 (13.7%) | 17 | 138 |
| **TSH 0.4–4.0 mIU/L** | 34545 (89.2%) | 14825 | 19720 | 670 (59.3%) | 68 | 602 |
| **TSH 4.01–10.0 mIU/L** | 3660 (9.4%) | 1169 | 2491 | 254 (22.5%) | 31 | 223 |
| **TSH ≥10.0 mIU/L** | 266 (0.7%) | 77 | 189 | 51 (4.5%) | 12 | 39 |
| **Total (n)** | 38736 | 16162 | 22574 | 1130 | 128 | 1002 |

*Participants reporting the use of thyroid blockers (methimazole or propylthiouracil), liothyronine, animal source thyroid hormone and amiodarone were excluded.

https://doi.org/10.1371/journal.pone.0242795.t004
how many individuals with a substantially elevated TSH level at baseline reported a new thyroid disorder during one of the follow-up questionnaires. Of the 70 participants with TSH level > 20.0 mIU/L without using thyroid hormone at baseline, only 18 reported the development of a new thyroid disorder. Reversely, we calculated that of 236 participants who reported a new hypothyroidism during follow-up, 119 (50.4%) were already using thyroid hormone supplementation at baseline.

Fig 2. Relationship between TSH and FT4 in participants with subclinical or overt hypothyroidism not using levothyroxine. The line indicates the linear regression relationship. Note that 98.4% of the individuals with a TSH between 4.01 and 10.0 mIU/L had a normal FT4 concentration (>11 pmol/L).

Table 5. Distribution of TSH class per age group (in %) in participants not using thyroid medication or amiodarone at baseline.

| Age group (years) | N   | <0.40 | 0.40–4.0 | 4.01–10.0 | >10.0 |
|------------------|-----|-------|----------|-----------|-------|
| 18–29            | 5111| 0.4   | 86.1     | 13.0      | 0.5   |
| 30–39            | 8017| 0.5   | 92.2     | 6.7       | 0.6   |
| 40–49            | 13365| 0.7   | 91.0     | 7.7       | 0.6   |
| 50–59            | 6793| 0.7   | 88.0     | 10.3      | 1.0   |
| 60–69            | 4253| 1.1   | 84.9     | 13.2      | 0.8   |
| 70–79            | 1084| 1.1   | 84.0     | 13.9      | 1.0   |
| ≥80              | 113 | 6.2   | 77.0     | 16.8      | 0.0   |

https://doi.org/10.1371/journal.pone.0242795.t005
Discussion

Prevalence of thyroid disorders based on use of thyroid medication

In the Lifelines Cohort Study, we showed that the overall prevalence of diagnosed and treated thyroid disorders (hypothyroidism plus thyrotoxicosis), assessed by medication use, is 3.1%. Compared to the NIVEL G.P. registration, the prevalence of hypothyroidism (defined as levothyroxine supplementation) in male Lifelines participants was similar. In females the prevalence of hypothyroidism appeared to be higher. Thyroid hormone measurements in a subset of almost 40000 participants showed that the prevalence of unknown / undetected subclinical hypothyroidism was 9.4%, while the prevalence of undetected overt hypothyroidism was 0.7%. As expected, the use of levothyroxine increased with age. However, only 59.3% of users of levothyroxine had a TSH level within the normal range, meaning that possibly a large proportion is being undertreated (TSH >4.0 mIU/L, 27%) or overtreated (TSH <0.4 mIU/L, 13.7%).

In comparison with the NIVEL G.P. registrations, the estimated prevalence of hypothyroidism in Lifelines was similar in men, but in women it was higher except in those >85 years. This difference may be a consequence of the different way how hypothyroidism was defined, i.e. ICPC T86 coding (NIVEL) versus use of levothyroxine (Lifelines). Also, the time period in which data have been collected differed slightly, i.e. 2007–2013 in Lifelines, and 2013 in the NIVEL / G.P. registration. It should be noted that there is very limited information on how well hypothyroidism is diagnosed and scored in general practice. Research by NIVEL indicated that slightly over 80% of patients using thyroid hormone had a concomitant T86 ICPC code (registered hypothyroidism / myxoedema) [28]. The assumption that over 90% of levothyroxine users have this medication prescribed because of primary hypothyroidism may lead to the conclusion that there is a 10% underreporting. In addition, a recent report on the consequences of the temporary withdrawal of the ThyraxR brand from the Dutch market mentioned that about 8% of levothyroxine users only used a dose of 25 mcg per day or less [29], suggesting that a considerable number of patients labelled with ICPC code T86 had subclinical and not overt hypothyroidism. This may also apply to the Lifelines dataset.

Prevalence and incidence of thyroid disorders based on thyroid hormone levels

In Lifelines participants, a new diagnosis of overt hypothyroidism (TSH >10.0 mIU/L) was made in 0.7%, while the prevalence of subclinical hypothyroidism was 9.4%. A significant number (61%) of participants with TSH >10.0 mIU/L still had normal FT4 levels. Over the previous decades, the (reported) prevalence of thyroid disease has changed. One of the first studies to evaluate thyroid function on a large scale in the population was the Whickham Survey, which was conducted between 1972 and 1974 [30]. The prevalence of established hypothyroidism was 1.4% in women and 0.1% in men. Five new cases of overt hypothyroidism were found (0.35%), while prevalence of elevated TSH (defined as ≥6.0 mIU/L) was 7.5% in women and 2.8% in men [30]. It must be realized that in those days, treatment was different (thyranon, thyroid powder), and immunoassays were less developed. In 1985, the Framingham study reported that the prevalence of hypothyroidism was 4.4% (95/2139 participants over the age of 60 years), with a higher prevalence in women (5.9%) compared to men (2.4%). Prevalence of subclinical hypothyroidism (defined as TSH 5.0–10.0 mIU/L) was 5.9% [31]. In a follow-up study of the Whickham Survey, the incidence of hypothyroidism was calculated to be 3.5 per 1000 per year in women and 0.6 per 1000 per year in men [32]. Other studies, summarized by Vanderpump in an extensive review in 2011, reported a prevalence of previously undiagnosed overt hypothyroidism between 0 and 7.8 per 1000 men, and 3.0 and 20.5 per 1000 women [33].
Data from 1995–1997 in Norway were similar, with a prevalence of treated hypothyroidism of 4.8% in women and 0.89% in men, and a clear increase of prevalence with higher age [34]. In addition, the prevalence of undiagnosed hypothyroidism (TSH ≥10.0 mIU/L) was 0.9% in women and 0.37% in men, while the prevalence of subclinical hypothyroidism was 5.1 and 3.7%, respectively [34]. In a follow-up study between 2006–2008 from HUNT, the prevalence of undiagnosed overt as well as subclinical hypothyroidism had declined considerably, while the prevalence of treated hypothyroidism had increased from 5.0 to 8.0% in women, and from 1.0 to 2.0% in men [2]. The explanation of the investigators for these changes were increased thyroid function testing as well as earlier levothyroxine treatment for subclinical hypothyroidism [2]. A similar trend was observed between 2000 and 2010 surveys in Pomerania [35]. This may suggest that a significant number of individuals is treated with thyroid hormone supplementation without possible medical necessity [36]. Over 60% of individuals in whom subclinical hypothyroidism is established, thyrotropin declines to the normal range over 5 years [36]. Too liberal thyroid hormone treatment in individuals with moderately elevated TSH levels may be one of the factors responsible for differences in medication use between studies. This trend could also be observed in the Thyroid Epidemiology Audit and Research Study (TEARS) in Tayside, UK, where almost half of the individuals who started taking thyroid hormone supplementation had a TSH level < 6.0 mIU/L [37]. Similar mechanisms may explain the higher prevalence of levothyroxine use between NHANES and Lifelines (Table 3).

Other reasons for the difference in prevalence may be differences in reference values. One study in Korea based its reference values for TSH, measured with similar methodology as in our present study, on the 2.5th and 97.5th percentile of TSH values in subjects with no prior history of thyroid disease, no family history of disease, negative TPO-antibodies, and serum FT4 levels in the reference range [38]. This yielded a reference value for TSH from 0.62 to 6.86 mIU/L, which significantly lowers the percentage of individuals with subclinical hypothyroidism compared to our reference values. A study in France suggested the use of age-specific and sex-specific reference values for TSH, with upper-limit reference values > 5.0 mIU/L for women over the age of 70 [39]. This might partly explain the large number of individuals with a normal FT4 in combination with a slightly elevated TSH in the current study.

**Prevalence of abnormal TSH levels in individuals using levothyroxine**

Previous research has clearly shown that - with TSH levels in the normal range - FT4 levels were significantly higher and yet FT3 levels were significantly lower (p < 0.001 in both cases) in levothyroxine-treated athyroid patients than in matched euthyroid control subjects [40]. In Lifelines participants using levothyroxine, only 59.3% had TSH levels within the normal range, while 27% had a TSH > 4.0 mIU/L and appeared to be undertreated, and 13.7% had a suppressed TSH level and was possibly overtreated. Similarly, in 2000 the Colorado Thyroid Disease Prevalence Study reported that 60% of individuals using thyroid medication had a normal TSH level [41]. The same study reported that the percentage of participants taking thyroid medication with subclinical hyperthyroidism (TSH between 0.01–0.3 mIU/L) was 20%, while 17% had subclinical hypothyroidism (TSH > 5.1 mIU/L and total T4 > 57.9 nmol/L) [41]. Similar data were reported in the UK and Brasil, with the latter study showing poorer health-related quality of life associated with undertreatment [42, 43]. A recent study in The Netherlands evaluating a levothyroxine brand switch amongst individuals with hypothyroidism treated in general practice showed that 67% of participants had a TSH level within the reference range [29]. The reasons for this are not clear. On the one hand, doctors may ignore the significance of elevated TSH levels when concomitant measurements show an FT4 level within the normal range. On the other hand, it may well be that despite an elevated TSH,
levothyroxine dose is not increased when patients do not report any complaints. TSH levels may vary over time, however, and a G.P. may decide not to alter the dose when the previous TSH level was within the target. The Dutch guidelines for G.P.’s nevertheless mention that with optimal supplementation, TSH is in the low-normal range of 0.5–2.0 mIU/L, and FT4 then is ‘high-normal’ [44].

Validity of the obtained thyroid data

The extensive set of data collected by Lifelines supports its merits for thyroid-oriented research. Previously we have reported in smaller-sized studies based on baseline Lifelines data on the relationship between thyroid hormone levels and health-related quality of life [13], and metabolic syndrome [18], and the effect of the Thr92Ala polymorphism on thyroid function and health-related quality of life [21]. Also, in Lifelines genome-wide association study (GWAS) studies have been performed in over 13000 participants, and Lifelines data have contributed to several genetic evaluations including those related to thyroid function [45, 46].

Because of the longitudinal design, the Lifelines study may offer additional opportunities to expand our knowledge on the natural course of (subclinical) hypothyroidism and its complications. We observed a 0.7% prevalence of elevated TSH \( > 10 \) mIU/L within the subset of Lifelines’ participants not using thyroid medication with thyroid function measured. This implies that approximately 800 of the 112000 Lifelines participants in whom thyroid hormone was not measured, a TSH level \( > 10.0 \) mIU/L could have been found. At follow-up, at least 778 new diagnoses of hypothyroidism and 317 unspecified thyroid disorders have been reported by participants (S5 Table). Also, 3660 participants had a TSH level between 4.0 and 10.0 mIU/L. Considering the current collection of information of Lifelines participants, these further investigations should be done in substudies in which additional data are collected, and verification of diagnosis and medication through G.P.’s charts and pharmacists’ prescription data is indicated. Also, to better classify the relevance of subclinical hypothyroidism, measurement of anti-TPO antibodies would be of value. Currently such connections are being made, bringing an integrated big data approach where biobanks and clinical datasets are connected [47].

At baseline, one of the most important sources for establishing diagnoses and co-morbidities was the list of medication used by a participant. Medication has been shown to be a powerful indicator for (co-)morbidty [48, 49], health-related quality of life, and even severity of disease [50, 51]. Also the studies in Tayside, UK, considered medication use as the most important source for classifying participants with thyroid dysfunction [37]. Unfortunately, no data are available on the use of new medications or changes in medication at follow-up in Lifelines. Medication use like levothyroxine or methimazole can validate the self-reported diagnosis of hypothyroidism and thyrotoxicosis, or even ascertain the presence of a thyroid disorder when a participant did not report this correctly in the questionnaire. However, it must be noted that thyroid hormone supplementation is prescribed both in case of primary and secondary hypothyroidism. From the current dataset, we could not differentiate between these two causes, although epidemiologic data suggest that the majority of levothyroxine use is for primary hypothyroidism, either Hashimoto’s hypothyroidism or hypothyroidism after treatment of thyrotoxicosis with surgery or radioactive iodine. Concomitant use of for instance hydrocortisone, sex hormones like testosterone and / or growth hormone could suggest the presence of secondary hypothyroidism. However, pituitary insufficiency comes in many variants, and also primary hypothyroidism and primary adrenal insufficiency (in case of hydrocortisone use) do co-exist. Adequate differentiation between both variants of hypothyroidism should therefore also be done by verification of G.P.’s charts.
Strengths and limitations

Our study has several strengths and weaknesses. We presented baseline data on 152180 participants within a broad range of age and comorbidities, and the results of thyroid function in one of the largest population-based thyroid hormone screenings available, with extensive phenotyping in several domains of health and disease. Limitations are mainly found in the questionnaires. The Lifelines open text questions at baseline allowed participants to report whether they had undergone thyroid surgery, and the follow-up questionnaires allowed to report whether they had developed a new thyroid disorder. Both proved not to be reliable and severely underestimate the true incidence and prevalence of thyroid disorders. The number of answers to the question HEALTH73 (Do you have or have you had another disorder that you have not mentioned yet?) is only a fraction of the number of individuals who were using thyroid hormone supplementation. By extrapolation, we assume that the same holds true for the question regarding previous surgery for a thyroid disorder (HEALTH74). The majority of answers (55%) just mentioned thyroid surgery without any details on cause or type of procedure. In agreement with advices described in a 2009 editorial [52], the Lifelines questionnaires specifically ask for the history of several diseases as recognized and recalled by the patient, for instance several types of cardiovascular disease, osteoporosis, diabetes, hypertension, cancer, rheumatoid arthritis and inflammatory bowel diseases. However, the only specific questions asking for a thyroid disorder are the questions on current (HEALTH66) and past (HEALTH67) use of medication for a thyroid disorder. Even when such a specific question is introduced in future questionnaires, we can discuss how well they will be answered. Over half of the participants who reported earlier use of thyroid medication still was using medication at baseline screening. In addition, 10% of participants who answered that they underwent thyroid surgery, reported a cyst as a reason for surgery, which is not current practice in our country. Also, only a limited number of the participants who were found to have severely elevated TSH levels at baseline screening, reported a new thyroid disorder in one of the follow-up questionnaires. It should be noted that all TSH levels >10.0 mIU/L were communicated with the G.P. of a participant, with the advice (depending on the level of TSH) to re-check if needed, and otherwise to start levothyroxine supplementation. As mentioned earlier, validation of diagnoses and previous surgical procedures can be realised by exchanging data with charts of G.P.’s practices, and by collecting surgical notes from hospital charts. Lifelines is in an excellent position to increase its value and significance this way, especially because all health-related information is collected in the practice of the G.P., who plays a central role in the Dutch health care system.

Conclusion

The population prevalence of treated thyroid disorders in Lifelines is 3.1%. In those not known to have a thyroid disorder, the prevalence of primary hypothyroidism is 0.7%, and of subclinical hypothyroidism is 9.4%. Furthermore, 0.7% has a suppressed TSH. Only 59.3% of those participants who use levothyroxine have a TSH level in the normal range. Reliable ascertainment of previous and new thyroid disorders is not possible based on the currently used questionnaires. The large group of individuals with subclinical hypothyroidism offers an excellent possibility to prospectively follow the natural course of this disorder. However, both structured questions as well as linking to G.P.’s and pharmacists’ data are necessary to improve the completeness and reliability of data on thyroid disorders.

Supporting information

S1 Table. Baseline characteristics of the 152180 participants.

(DOCX)
S2 Table. Thyroid hormone levels measured at baseline in 39935 Lifelines participants.
(DOCX)

S3 Table. Distribution of TSH class per age group (in %) in NHANES participants not using thyroid hormone medication at baseline.
(DOCX)

S4 Table. Self-reported thyroid disorders or previous surgery using open questions at baseline.
(DOCX)

S5 Table. Self-reported thyroid disorders using open questions asking for other disorders during the follow-up questionnaires.
(DOCX)

Acknowledgments
The authors wish to acknowledge the services of the Lifelines Cohort Study, the contributing research centres delivering data to Lifelines, and all the study participants.

Author Contributions
Conceptualization: Melanie M. van der Klauw, Bruce H. R. Wolffenbuttel.
Formal analysis: Hanneke J. C. M. Wouters, Bruce H. R. Wolffenbuttel.
Investigation: Anneke C. Muller Kobold.
Resources: Anneke C. Muller Kobold.
Writing – original draft: Hanneke J. C. M. Wouters, Bruce H. R. Wolffenbuttel.
Writing – review & editing: Hanneke J. C. M. Wouters, Sandra N. Slagter, Anneke C. Muller Kobold, Melanie M. van der Klauw, Bruce H. R. Wolffenbuttel.

References
1. Virta LJ, Eskelinen SI. Prevalence of hypothyroidism in Finland—a nationwide prescription study. Eur J Clin Pharmacol. 2011; 67(1): 73–7. https://doi.org/10.1007/s00228-010-0884-4 PMID: 20809083.
2. Asvold BO, Vatten LJ, Bjoro T. Changes in the prevalence of hypothyroidism: the HUNT Study in Norway. European journal of endocrinology / European Federation of Endocrine Societies. 2013; 169(5): 613–20. https://doi.org/10.1530/EJE-13-0459 PMID: 23975540.
3. Garmendia Madariaga A, Santos Palacios S, Guillem-Grima F, Galofre JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014; 99(3): 923–31. https://doi.org/10.1210/jc.2013-2409 PMID: 24423323.
4. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006; 295(9): 1033–41. https://doi.org/10.1001/jama.295.9.1033 PMID: 16507804.
5. Schultz M, Kistorp C, Raymond I, Dimsits J, Tuxen C, Hildebrandt P, et al. Cardiovascular events in thyroid disease: a population based, prospective study. Horm Metab Res. 2011; 43(9): 653–9. https://doi.org/10.1055/s-0031-1283162 PMID: 21823062.
6. Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012; 172(10): 799–809. https://doi.org/10.1001/archinternmed.2012.402 PMID: 22529182.
7. Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015; 313(20): 2055–65. https://doi.org/10.1001/jama.2015.5161 PMID: 26010634.
8. Asvold BO, Vatten LJ, Nilsen TI, Bjoro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol. 2007; 156 (2): 181–6. https://doi.org/10.1530/eje.1.02333 PMID: 17287407.

9. Mazzeffi MA, Lin HM, Flynn BC, O’Connell TL, DeLaet DE. Hypothyroidism and the risk of lower extremity arterial disease. Vasc Health Risk Manag. 2010; 6: 957–62. https://doi.org/10.2147/VHRM.S13535 PMID: 21057580.

10. Journy NMY, Bernier MO, Doody MM, Alexander BH, Linhaara CM. Hyperthyroidism, Hypothyroidism, and Cause-Specific Mortality in a Large Cohort of Women. Thyroid 2017; 27(8): 1001–10. https://doi.org/10.1089/thy.2017.0063 PMID: 28578598.

11. Jorgensen P, Langhammer A, Kroekstad S, Forosmo S. Mortality in persons with undetected and diagnosed hypertension, type 2 diabetes, and hypothyroidism, compared with persons without corresponding disease—a prospective cohort study: The HUNT Study, Norway. BMC Fam Pract. 2017; 18(1): 98. https://doi.org/10.1186/s12875-017-0672-7 PMID: 29212453.

12. Mammen JS, McGready J, Oxman R, Chia CW, Ladenson PW, Simonsick EM. Thyroid Hormone Therapy and Risk of Thyrotoxicosis in Community-Resident Older Adults: Findings from the Baltimore Longitudinal Study of Aging. Thyroid 2015; 25(9): 979–86. https://doi.org/10.1089/thy.2015.0180 PMID: 26177259.

13. Klaver EI, van Loon HC, Stienstra R, Links TP, Kema IP, et al. Thyroid hormone status and health-related quality of life in the LifeLines Cohort Study. Thyroid. 2013; 23(9): 1066–73. https://doi.org/10.1089/thy.2013.0017 PMID: 23530992.

14. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010; 95(1): 186–93. https://doi.org/10.1210/jc.2009-1625 PMID: 19906785.

15. Klein Hesselink EN, Klein Hesselink MS, de Bock GH, Gansevoort RT, Bakker SJ, Vredeveld EJ, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol. 2013; 31(32): 4046–53. https://doi.org/10.1200/JCO.2013.49.1043 PMID: 24101052.

16. Stolk RP, Rosmalen JG, Postma DS, de Boer RA, Navis G, Slaets JP, et al. Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study. Eur J Epidemiol. 2008; 23(1): 67–74. https://doi.org/10.1007/s10654-007-9204-4 PMID: 18075776.

17. Scholtens S, Smidt N, Swertz MA, Bakker SJ, Dotinga A, Vonk JM, et al. Cohort Profile: LifeLines, a three-generation cohort study and biobank. Int J Epidemiol. 2015; 44(4): 1172–80. https://doi.org/10.1093/ije/dyu229 PMID: 25502107.

18. Wolfenbuttel BHR, Wouters HJCM, Slagter SN, van Waateringe RP, Muller Kobold AC, van Vliet-Ostaptchouk JV, et al. Thyroid function and metabolic syndrome in the population-based LifeLines cohort study. BMC Endocr Disord. 2017; 17(1): 65. https://doi.org/10.1186/s12902-017-0215-1 PMID: 29037214.

19. Klijns B, Scholtens S, Mandemakers JJ, Snieder H, Stolk RP, Smidt N. Representativeness of the LifeLines Cohort Study. PloS one. 2015; 10(9): e0137203. https://doi.org/10.1371/journal.pone.0137203 PMID: 26333164.

20. van Waateringe RP, Slagter SN, van der Klauw MM, van Vliet-Ostaptchouk JV, Graaff R, Paterson AD, et al. Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study. Eur J Clin Invest. 2016; 46(5): 481–90. https://doi.org/10.1111/eci.12627 PMID: 27002914.

21. Wouters HJ, van Loon HC, van der Klauw MM, Elderson MF, Slagter SN, Kobold AM, et al. No Effect of the Thr92Ala Polymorphism of Deiodinase-2 on Thyroid Hormone Parameters, Health-Related Quality of Life, and Cognitive Functioning in a Large Population-Based Cohort Study. Thyroid. 2017; 27(2): 147–55. https://doi.org/10.1089/thy.2016.0199 PMID: 27786042.

22. Bartalena L, Bogazzi F, Chiavota L, Hubaleska-Dydejczyk A, Links TP, Vanderpump M. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J. 2018; 7(2): 55–66. https://doi.org/10.1159/000486957 PMID: 29594056.

23. National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2003–2004. https://www.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=2003 [accessed March 31, 2020].

24. Bailey RL, Durazo-Arvizu RA, Carmel R, Green R, Pfeiffer CM, Sembros CT, et al. Modeling a methylmalonic acid-derived change point for serum vitamin B-12 for adults in NHANES. Am J Clin Nutr. 2013; 98(2): 460–7. https://doi.org/10.3945/ajcn.113.061234 PMID: 23803883.

25. Questionnaires, Datasets, and Related Documentation, National Health and Nutrition Examination Survey. Available from: https://www.cdc.gov/nchs/nhanes/default.aspx [accessed March 31, 2020].
26. Verkaik-Kloosterman J, Buurma-Rethans EJM, Dekkers ALM, van Rossum CTM. Decreased, but still sufficient, iodine intake of children and adults in the Netherlands. Br J Nutr. 2017; 117(7): 1020–31. https://doi.org/10.1017/S0007114517000733 PMID: 28516817.

27. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644 PMID: 19805654.

28. https://www.nivel.nl/sites/default/files/documentatie_episodeconstructie_niveau_1juli2016_definitief.pdf [accessed April 2, 2020].

29. Flinterman LE, Kuiper JG, Korevaar JC, van Dijk L, Hek K, Houben E, et al. Impact of a Forced Dose-Equivalent Levothyroxine Brand Switch on Plasma Thyrotropin: A Cohort Study. Thyroid 2020; 30(6): 821–8. https://doi.org/10.1089/thy.2019.0414 PMID: 3218356.

30. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977; 7(6): 481–93. https://doi.org/10.1111/j.1365-2265.1977.tb01340.x PMID: 598014.

31. Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P. The aging thyroid. Thyroid deficiency in the Framingham Study. Arch Intern Med. 1985; 145(8): 1386–8. PMID: 4026469.

32. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995; 43(1): 55–68. https://doi.org/10.1111/j.1365-2265.1995.tb01894.x PMID: 7641412.

33. Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull. 2011; 99: 39–51. https://doi.org/10.1093/bmb/ldr030 PMID: 21893493.

34. Bjoro T, Holmen J, Kruger O, Midthjell K, Hunstad K, Schreiner T, et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol. 2000; 143(5): 639–47. https://doi.org/10.1530/eje.0.1436-039 PMID: 11078988.

35. Khattak RM, Ittermann T, Nauck M, Below H, Volzke H. Monitoring the prevalence of thyroid disorders in the adult population of Northeast Germany. Popul Health Metr. 2016; 14: 39. https://doi.org/10.1186/s12963-016-0111-3 PMID: 27833458.

36. Biondi B, Cappola AR, Cooper DS. Subclinical Hypothyroidism: A Review. JAMA. 2019; 322(2): 153–60. https://doi.org/10.1001/jama.2019.9052 PMID: 32183257.

37. Leese GP, Flynn RV, Jung RT, Macdonald TM, Murphy MJ, Morris AD. Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: the Thyroid Epidemiology Audit and Research Study (TEARS). Clin Endocrinol (Oxf). 2008; 68(2): 311–6. https://doi.org/10.1111/j.1365-2265.2007.03051.x PMID: 17973071.

38. Kim WG, Kim WB, Woo G, Kim H, Cho Y, Kim TY, et al. Thyroid Stimulating Hormone Reference Range and Prevalence of Thyroid Dysfunction in the Korean Population: Korea National Health and Nutrition Examination Survey 2013 to 2015. Endocrinol Metab (Seoul). 2017; 32(1): 106–14. https://doi.org/10.3803/EnM.2017.32.1.106 PMID: 28116874.

39. Raverot V, Bonjour M, Abellon du Payrat J, Perrin P, Roucher-Boulez F, Lasolle H, et al. Age- and Sex-Specific TSH Upper-Limit Reference Intervals in the General French Population: There Is a Need to Adjust Our Actual Practices. J Clin Med. 2020; 9(3): 792. https://doi.org/10.3390/jcm9030792 PMID: 32193257.

40. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PloS one. 2011; 6(8): e22552. https://doi.org/10.1371/journal.pone.0022552 PMID: 21829633.

41. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000; 160(4): 526–34. https://doi.org/10.1001/archinte.160.4.526 PMID: 10695693.

42. Okosime OE, Belludi G, Spittle K, Kadiyala R, Richards J. Adequacy of thyroid hormone replacement in a general population. QJM. 2011; 104(5): 395–401. https://doi.org/10.1093/qjmed/hcq222 PMID: 21109503.

43. Vigario Pdos S, Vaisman F, Coeli CM, Ward L, Graf H, Carvalho G, et al. Inadequate levothyroxine replacement for primary hypothyroidism is associated with poor health-related quality of life in a Brazilian multicentre study. Endocrine. 2013; 44(2): 394–40. https://doi.org/10.1007/s12020-013-9869-1 PMID: 23371817.

44. Sijbom M, van Lieshout J, Felix-Scholtaart B, Burgers JS, Bouma M. [Summary of the 'Thyroid disorders' guideline of the Dutch College of General Practitioners (NHG)]. Ned Tijdscr Geneesk. 2013; 157(35): A6667. PMID: 23985246.
45. Porcu E, Medici M, Pistis G, Volpato CB, Wilson SG, Cappola AR, et al. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS genetics. 2013; 9(2): e1003266. https://doi.org/10.1371/journal.pgen.1003266 PMID: 23408906.

46. Teumer A, Chaker L, Groeneweg S, Li Y, Di Munno C, Barbieri C, et al. Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation. Nat Commun. 2018; 9(1): 4455. https://doi.org/10.1038/s41467-018-06356-1 PMID: 30367059.

47. Sediq R, van der Schans J, Dotinga A, Alingh RA, Wilffert B, Bos JH, et al. Concordance assessment of self-reported medication use in the Netherlands three-generation Lifelines Cohort study with the pharmacy database iaDB.nl: The PharmLines initiative. Clin Epidemiol. 2018; 10: 981–9. https://doi.org/10.2147/CLEP.S163037 PMID: 30147377.

48. Schubert CC, Boustani M, Callahan CM, Perkins AJ, Carney CP, Fox C, et al. Comorbidity profile of dementia patients in primary care: are they sicker? J Am Geriatr Soc. 2006; 54(1): 104–9. https://doi.org/10.1111/j.1532-5415.2005.00543.x PMID: 16420205.

49. Vitry A, Wong SA, Roughhead EE, Ramsay E, Barratt J. Validity of medication-based co-morbidity indices in the Australian elderly population. Aust N Z J Public Health. 2009; 33(2): 126–30. https://doi.org/10.1111/j.1753-6405.2009.00357.x PMID: 19413854.

50. Halling A, Fridh G, Ovhed I. Validating the Johns Hopkins ACG Case-Mix System of the elderly in Swedish primary health care. BMC Public Health 2006; 6: 171. https://doi.org/10.1186/1471-2458-6-171 PMID: 16805909.

51. Starfield B, Kinder K. Multimorbidity and its measurement. Health Policy. 2011; 103(1): 3–8. https://doi.org/10.1016/j.healthpol.2011.09.004 PMID: 21963153.

52. Barr EL, Tonkin AM, Welborn TA, Shaw JE. Validity of self-reported cardiovascular disease events in comparison to medical record adjudication and a statewide hospital morbidity database: the AusDiab study. Intern Med J. 2009; 39(1): 49–53. https://doi.org/10.1111/j.1445-5994.2008.01864.x PMID: 19290982.